Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantationECCO '18 Vienna
Year: 2018
Authors:

M. Peverelle*, C. Mills, A. Testro, P. de Cruz

Austin Health, Gastroenterology and Hepatology, Melbourne, Australia

P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studiesECCO '18 Vienna
Year: 2018
Authors:

E. Krishnan*, N. Zhang, H. Wang

Amgen Inc., Biosimilars, Thousand Oaks, USA

P498: Crohn’s disease patient’s isolated classical monocytes are characterised by reduced secretion of Wnt-ligands affecting Paneth cell antimicrobial host defenseECCO '18 Vienna
Year: 2018
Authors:

N.S. Armbruster*, U. Denzau-Graupner, T. Klag, M. Götz, N. Malek, J. Wehkamp

University Hospital Tübingen, Internal Medicine I, Tübingen, Germany

P499: A comparison of health-related quality of life in nurse-led vs. conventional inflammatory bowel disease follow-upECCO '18 Vienna
Year: 2018
Authors:

L. Alvestad1*, L.-P. Jelsness-Jørgensen2,3, R. Goll4, A. Clancy5, P.C. Valle6, A.R. Broderstad7

1UiT, The Arctic University of Norway, Department of Health and Care Sciences, Harstad, Norway, 2Østfold University College, Fredrikstad, Norway, Fredrikstad, Norway, 3Østfold Hospital Trust, Department of Gastroenterology, Kalnes, Norway, 4University Hospital of North Norway, UNN, Tromsø, Norway, 5UiT, The Arctic University of Norway, Department of Health and Care Sciences, Harstad, Norway, Harstad, Norway, 6University Hospital of North Norway, Harstad, Norway, 7UiT, The Arctic University of Norway, Harstad, Norway

P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?ECCO '18 Vienna
Year: 2018
Authors:

T. Ahmed1, F. Brown1, R. Ahmed1, S. Whitehead2, H. Steed1, M.J. Brookes1*

1Royal Wolverhampton NHS Trust, Gastroenterology Unit, Wolverhampton, UK, 2Royal Wolverhampton NHS Trust, Clinical Biochemistry Unit, Wolverhampton, UK

P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reportsECCO '18 Vienna
Year: 2018
Authors:

P. Drastich*, J. Brezina, L. Bajer, M. Benes, J. Spicak

Institute of Clinical and Experimental Medicine, Hepatogastroenterology, Prague, Czech Republic

P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control studyECCO '18 Vienna
Year: 2018
Authors:

T. Miyazaki1*, A. Fujimori1, R. Koshiba1, K. Fujimoto1, T. Sato1, M. Kawai2, Y. Kita1, K. Kamikozuru1, T. Takagawa2, Y. Yokoyama1, N. Hida1, K. Watanabe2, S. Nakamura1

1Hyogo College of Medicine, Inflammatory Bowel Disease, Nishinomiya, Japan, 2Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan

P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?ECCO '18 Vienna
Year: 2018
Authors:

A. Walsh1*, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, M. Peters5, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, G. Collins6, S. Travis1

1John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, UK, 2Mathematical Institute, Oxford, UK, 3Big Data Institute, Oxford, UK, 4University of Oxford, Psychiatry Department, Oxford, UK, 5University of Oxford, Nuffield Department of Population Health, Oxford, UK, 6University of Oxford, Centre for Statistics in Medicine, Oxford, UK

P504: The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Sollelis1,2*, R. Minet Quinard3, G. Bouguen4, M. Goutte1,2, F. Goutorbe1,5, D. Bouvier3, B. Pereira6, G. Bommelaer1,2, A. Buisson1,2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the Host, Clermont-Ferrand, France, 3University Hospital G. Montpied, Biochemistry Laboratory, Clermont-Ferrand, France, 4University Hospital, Rennes, France, 5Hospital of Bayonne, Gastroenterology Department, Bayonne, France, 6University Hospital, Biostatistics Unit, DRCI Clermont-Ferrand, France

P505: Factors influencing outcomes from surgery for Crohn’s disease: A perspective from a district hospitalECCO '18 Vienna
Year: 2018
Authors:

A.R. Aspari*, N. Husain, P. Thomas

Burton Hospitals NHS Foundation Trust, Colorectal Surgery, Burton On Trent, UK

P506: Incidence risk of colorectal cancer, non-melanoma skin cancers and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on large-scale claims databaseECCO '18 Vienna
Year: 2018
Authors:

T. Kobayashi1*, A. Uda2, T. Mineyama2, E. Udagawa2, K. Iwasaki3, W. Tang3, T. Hibi1

1Center for Advanced IBD Research and Treatment, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan, 2Takeda Pharmaceutical Company Limited, Tokyo, Japan, 3Milliman, Inc., Tokyo, Japan

P507: What is the impact of infliximab metaoptimisation on surgical rates and need-to-change-therapy in real-world practice for severe inflammatory bowel disease?ECCO '18 Vienna
Year: 2018
Authors:

T. Lefebvre1, R. Cormons1, J.-L. Faucheron2, M. Baudrant3, B. Bonaz1, N. Mathieu4*

1Grenoble Alpes University Hospital, University Clinic of Hepato-Gastroenterology, Grenoble, France, 2Grenoble Alpes University Hospital, Colorectal Unit Department of Surgery, Grenoble, France, 3Grenoble Alpes University Hospital, Department of Pharmacy, Grenoble, France, 4CHU Grenoble Alpes, University Clinic of Hepato-Gastroenterology, Grenoble, France

P508: Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in KoreaECCO '18 Vienna
Year: 2018
Authors:

J.Y. Chang*, S.-A. Jung, C.M. Moon, S.-E. Kim, H.-K. Jung, K.-N. Shim

Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea

P509: Long-term outcomes in biologic-treated perianal Crohn’s fistulaECCO '18 Vienna
Year: 2018
Authors:

S. Adegbola1*, W.Y. Mak2, K. Sahnan1, P. Tozer1,3, P. Bassett4, S. Hiles5, R. Phillips1, J. Warusavitarne1,3, O. Faiz1,3, A. Hart1,2

1St Mark’s Academic Institute, Robin Phillip’s Fistula Research Unit, London, UK, 2St Mark’s Hospital, Department of IBD, London, UK, 3St Mark’s Hospital, Department of Surgery, London, UK, 4St Mark’s Academic Institute, London, UK, 5LNWH ST MARKS HOSPITAL, Harrow, UK

P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBDECCO '18 Vienna
Year: 2018
Authors:

F. Schoenefuss*, P. Hoffmann

Kliniken Essen Mitte, Gastroenterology, Essen, Germany

P511: Early prediction of steroid failure in acute severe ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

M.C. Choy1,2,3*, K. Boyd4, R. Burder4, A. Gorelik5, R. Nallas6, J. Horvath6, Q. Lam6, N. Crinis6, D. Van Langenberg7, M. Sparrow8, W. Connell3, K. Visvanathan3,9, P. De Cruz1,2

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2University of Melbourne, Austin Academic Centre, Melbourne, Australia, 3St. Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia, 4Austin Health, Gastroenterology, Melbourne, Australia, 5Australian Catholic University, Melbourne, Australia, 6Austin Health, Pathology, Melbourne, Australia, 7Eastern Health, Gastroenterology, Melbourne, Australia, 8Alfred Health, Gastroenterology, Melbourne, Australia, 9University of Melbourne, Medicine, Melbourne, Australia

P512: Herpes zoster infection in patients with ulcerative colitis receiving tofacitinibECCO '18 Vienna
Year: 2018
Authors:

K.L. Winthrop1, G.Y. Melmed2, S. Vermeire3*, M.D. Long4, G. Chan5, R.D. Pedersen5, N. Lawendy5, A.J. Thorpe5, C.I. Nduaka5, C. Su5

1Oregon Health and Science University, Portland, OR, USA, 2Cedars-Sinai Medical Center, Division of Gastroenterology, Department of Medicine, Los Angeles, CA, USA, 3University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 4University of North Carolina, Center for Gastrointestinal Biology and Disease, Chapel Hill, NC, USA, 5Pfizer Inc., Collegeville, PA, USA

P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort studyECCO '18 Vienna
Year: 2018
Authors:

R. Frei1, N. Fournier2, J. Zeitz3, M. Scharl1, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Lausanne, IUMSP, Lausanne, Switzerland, 3Klinik Hirslanden, Department of Gastroenterology, Zurich, Switzerland, 4University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 5CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland, 6 Center of Gastroenterology and Hepatology, Zurich, Switzerland, 7University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

P514: Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small-molecule drugs in ulcerative colitis: A meta-analysisECCO '18 Vienna
Year: 2018
Authors:

F.S. Macaluso1*, M. Maida2, S. Renna1, M. Ventimiglia1, M. Cottone1, A. Orlando1

1Division of Internal Medicine, “'Villa Sofia-Cervello” Hospital, Palermo, Italy, 2Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy

P515: Manipulating the microbiome in paediatric acute severe colitis with a cocktail of antibiotics: A pilot randomised controlled trialECCO '18 Vienna
Year: 2018
Authors:

D. Turner1*, H. Vlamakis2, D. Marcus1, M. Yassour2, J. Bishai2, B. Yerushalmi3, A. Griffiths4, M. Aloi5, L. Albenberg6, K.-L. Kolho7, G. Abutbul1, A. Assa8, R. Xavier2, A. Levine9

1Shaare Zedek Medical Center, Institute of Pediatric Gastroenterology, Jerusalem, Israel, 2The Broad Institute of MIT and Harvard, Cambridge, Center for Computational and Integrative Biology, Mass. General Hospital, Boston, USA, 3Soroka Medical Center, Beer Sheva, Israel, 4SickKids, Toronto, Canada, 5Sapienza University of Rome, Rome, Italy, 6CHOP, Philadelphia, USA, 7Children’s Hospital, Helsinki University, Helsinki, Finland, 8Schneider's Children Hospital, Petach Tiqva, Israel, 9Wolfson Medical Center, Holon, Israel